BAM
BNGO icon

Belpointe Asset Management’s Bionano Genomics BNGO Stock Holding History

Belpointe Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4
Closed -$2.66K – 920
2023
Q1 		$2.66K Hold
4
– – ﹤0.01% 3229
2022
Q4 		$3.51K Buy
+4
New +$5.03K ﹤0.01% 3056

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belpointe Asset Management's BNGO Position: Q2 2023 in Review

Belpointe Asset Management sold out of Bionano Genomics (BNGO) in Q2 2023, closing a stake of 4 shares — an estimated $2.66K sold.

Belpointe Asset Management first reported a position in BNGO in Q4 2022 and held it in 2 quarters. The position peaked at $3.51K in Q4 2022. 108 funds tracked by Wall St. Rank hold BNGO as of Q2 2023.

  • Belpointe Asset Management reported no remaining Bionano Genomics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 4 Bionano Genomics shares in Q2 2023, an estimated $2.66K.
  • Belpointe Asset Management first reported a position in Bionano Genomics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Bionano Genomics position peaked at $3.51K in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.